May 20, 2015
The biotech venture company R-Tech Ueno announced on May 18 that it has signed a collaborative research agreement with Hokkaido University to develop the novel VAP-1 inhibitor RTU-1096 as a treatment for diabetic retinopathy and diabetic macular edema. RTU-1096 is...read more